Neo Borocillina Fluidificante Tosse (Ambroxol Hydrochloride)

Ambroxol increases the production of serous fluid in the bronchial glands and breaks down mucopolysaccharide fibers in mucus. This reduces mucus viscosity, making it easier for ciliary action and coughing to transport the secretions out of the airways, thereby improving clearance.

The appropriate dose of Ambroxol is determined by the prescribing healthcare professional based on the patient’s age, weight, severity of symptoms and local prescribing guidelines. Patients should follow the prescriber’s instructions and the product label.

Safety data for Ambroxol in pregnancy and lactation are limited. The product should only be used if the prescriber judges that the potential benefit outweighs any possible risk to the fetus or infant. Women who are pregnant or breastfeeding should discuss use with their healthcare provider.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ambroxol differs from simple expectorants such as guaifenesin by actively stimulating serous secretion and depolymerising mucus fibers, leading to a more pronounced reduction in viscosity. It is often preferred when thick, tenacious mucus is present, whereas other agents mainly increase the volume of airway secretions.

The product should be stored at ambient temperature, preferably below 25 °C, in its original packaging. It must be kept away from moisture, direct sunlight and sources of heat to maintain stability and potency.

Neo Borocillina Fluidificante Tosse is taken orally as directed by the prescriber. The tablet or liquid is swallowed with a glass of water, typically after meals, unless otherwise instructed. Do not crush or chew tablets unless the label specifically permits it.

Serious adverse reactions are rare but may include severe allergic responses such as rash, urticaria, angioedema, or Stevens‑Johnson syndrome, as well as liver enzyme elevations indicating hepatic involvement. Any signs of hypersensitivity or liver dysfunction should prompt immediate medical evaluation.

Individuals with a known hypersensitivity to Ambroxol or any other component of the formulation should avoid the product. Patients with severe hepatic impairment should use it only under close medical supervision, and children under the age recommended by the prescriber should not be given the medication.